NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
NuCana plc (NASDAQ: NCNA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $150.00 to $25.00. They now have an "outperform" rating on the stock.
NuCana plc (NASDAQ: NCNA) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study